This paper will review the current status of methotrexate (MTX) clinical pharmacology, with particular emphasis on recent progress in understanding the causes of drug toxicity and in averting such toxicity by routine monitoring.
|Original language||English (US)|
|Number of pages||4|
|Journal||Cancer Treatment Reports|
|State||Published - Dec 1 1981|
ASJC Scopus subject areas
- Cancer Research